SciBX: Science-Business eXchange Contents: November 15 2012, Volume 5 / Issue 45

TABLE OF CONTENTS November 15 2012, Volume 5 / Issue 45 Analysis Cover Story The Distillery: Therapeutics Autoimmune disease Cancer Infectious disease Neurology Pulmonary disease Various The Distillery: Techniques Disease models Drug platforms Imaging Markers Advertisement A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The October 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a focus feature on those active in Neuro-partnering. This week, find out about how you can collaborate with Riboxx Pharmaceuticals. New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Bringing macrocycles full circle Joanne Kotz doi:10.1038/scibx.2012.1176 At the recently held SciBX Innovation in Drug Discovery and Development Summit on macrocycles and constrained peptides, participants identified four areas of science in which work is needed to enable innovation in the field. Three of them—pharmacokinetics, cell permeability and oral bioavailability—aim to create an understanding of the rules that govern the behavior of macrocycles and thus enable developers to better identify drug-like compounds. The fourth one tackles the issue of targeting. Summit participants laid out a roadmap for progress across the various macrocycle platforms and concluded that much of the research should be done in the precompetitive setting. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Transmembrane protein 173 (STING; TMEM173) doi:10.1038/scibx.2012.1177 Mouse studies suggest inhibiting STING could help treat autoimmune disease triggered by extracellular host DNA. Full Text | PDF Cancer Top Jumonji domain containing 2C (JMJD2C; KDM4C) doi:10.1038/scibx.2012.1178 Cell culture, mouse and patient sample studies suggest inhibiting JMJD2C could help treat breast cancer. Full Text | PDF SET domain and mariner transposase fusion gene (SETMAR; METNASE) doi:10.1038/scibx.2012.1179 In vitro and mouse studies suggest ciprofloxacin could help sensitize tumors to chemotherapy. Full Text | PDF Epidermal growth factor receptor (EGFR) doi:10.1038/scibx.2012.1180 In vitro and mouse studies identified 2,8-dianilino-purine compounds that could help treat EGFR-mutant lung cancer. Full Text | PDF MicroRNA-29 (miR-29); c-Myc (MYC); histone deacetylase 3 (HDAC3); enhancer of zeste homolog 2 (EZH2) doi:10.1038/scibx.2012.1181 In vitro and mouse studies suggest increasing miR-29 expression by combined inhibition of HDAC3 and EZH2 could help treat MYC-overexpressing cancers. Full Text | PDF Indoleamine 2,3-dioxygenase (INDO; IDO) doi:10.1038/scibx.2012.1182 Mouse studies suggest Salmonella typhimurium engineered to express IDO small hairpin RNA could help treat melanoma. Full Text | PDF Not applicable doi:10.1038/scibx.2012.1183 Mouse studies identified a UV-radiation–independent mechanism contributing to melanoma development in fair-skinned patients that could be blocked to prevent the disease. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2012.1184 Mouse studies suggest a combination of neutralizing antibodies could help treat HIV. Full Text | PDF Neurology Top Not applicable doi:10.1038/scibx.2012.1185 Rat studies suggest blocking thalamocortical neuronal activity could help treat and prevent seizures. Full Text | PDF Pulmonary disease Top Poly(ADP-ribose) polymerase-3 (PARP-3) doi:10.1038/scibx.2012.1186 Cell culture and mouse studies suggest antagonizing PARP-3 could be useful for treating CF. Full Text | PDF Transient receptor potential vanilloid 4 (TRPV4; VRL2) doi:10.1038/scibx.2012.1187 Animal studies suggest inhibiting TRPV4 could help treat pulmonary edema. Full Text | PDF Various Top σ1 Receptor; σ2 receptor doi:10.1038/scibx.2012.1188 In vitro and mouse studies suggest adamantine phenylalkylamines could help treat cancer and reduce neuropathic pain induced by cancer drugs. Full Text | PDF Distillery: Techniques Disease models Top Crystal structures that model T cell receptor (TCR)-mediated nickel allergy doi:10.1038/scibx.2012.1189 Crystal structures that model TCR-mediated nickel allergy could help identify new strategies to treat or prevent the condition. Full Text | PDF Microfluidic device to model IL-2–induced pulmonary edema doi:10.1038/scibx.2012.1190 In vitro studies suggest a microfluidic device could be used to model pulmonary edema and identify molecules to prevent the disease. Full Text | PDF Drug platforms Top Bicyclic peptides conjugated to an albumin-binding peptide to extend serum half-life doi:10.1038/scibx.2012.1191 A study in mice suggests conjugating bicyclic peptides to an albumin-binding peptide could increase therapeutic duration. Full Text | PDF Sinefungin derivatives as small molecule chemical probes of SET domain–containing histone methyltransferase function doi:10.1038/scibx.2012.1192 Sinefungin derivatives could be used to probe the therapeutic potential of inhibiting SET domain–containing histone methyltransferases. Full Text | PDF Imaging Top Imaging cancer metastasis using aptamer-functionalized silica nanoparticles doi:10.1038/scibx.2012.1193 Aptamer-functionalized silica nanoparticles could be used to image tumor metastasis. Full Text | PDF Noninvasive, laser-based imaging through opaque scattering doi:10.1038/scibx.2012.1194 A noninvasive, laser-based approach to image through opaque scattering layers could be useful for imaging biological structures. Full Text | PDF Toll-like receptor 2 (TLR2) agonist–based fluorescent imaging of pancreatic tumors doi:10.1038/scibx.2012.1195 A TLR2 agonist–based imaging agent could aid surgical resection of pancreatic tumors. Full Text | PDF Markers Top Bcl2 homology domain 3 (BH3)-derived peptides to predict patient outcome in acute myelogenous leukemia (AML) doi:10.1038/scibx.2012.1196 A BH3 peptide–based assay could be used to predict outcomes for patients with AML in response to chemotherapy. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.